ARTV

Artiva Biotherapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Ra Capital Management, L.p.Director, 10 Percent Owner:
$4.3M548.6k shares
BuyJun 11, 2026
$7.91
$8.00
Ra Capital Management, L.p.Director, 10 Percent Owner:
$3.3M479k shares
BuyJun 9, 2026
$6.91
$8.00
Ra Capital Management, L.p.Director, 10 Percent Owner:
$721103 shares
BuyJun 10, 2026
$7.00
$8.00
5AM Partners VI, LLC10 Percent Owner
$10.0M833.3k shares
BuyJul 22, 2024
$12.00
--
Aslan FredDirector, Officer: President And CEO
$70k25.5k shares
SellAug 15, 2025
$2.73
--
Aslan FredDirector, Officer: President And CEO
$153k25.5k shares
SellOct 17, 2025
$6.00
--

News

globenewswire.comArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Todayglobenewswire.comJun 8prnewswire.comThe $13 Million Company Teaching the Immune System to Hunt Cancerprnewswire.comMay 29globenewswire.comArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 28globenewswire.comArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseasesglobenewswire.comMay 19globenewswire.comArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Developmentglobenewswire.comMay 19